TampelliniM., FilipskiE., LiuX.H., LemaigreG., LiX.M., VrignaudP., FrancoisE., BisseryM.C., LeviF.: Docetaxel chronopharmacology in mice. Cancer Res., 58: 3896–3904, 1998.
3.
GarufiC., LeviF., AschelterA., PaceR., GiuntaS., NisticoC., GallàD.A., SilecchiaG.F., FranchiF., NarduzziC., TerzoliE.: A phase I trial of five day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. Eur. J. Cancer, 33: 1566–1571, 1997.
4.
CaussanelJ.P., LéviF., BrienzaS., MissetJ.L., ItzhakiM., AdamR., MilanoG., HecquetB., MathéG.: Phase-I trial of 5-day continuous infusion of oxaliplatin at circadian-rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst., 82: 1046–1050, 1990.
5.
LéviF., PerpointB., GarufiC.: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 29: 1280–1284, 1993.
6.
GiacchettiS., PerpointB., ZidaniR., Le BailN., FaggiuoloR., FocanC., CholletP., LloryJ.F., LetourneauY., CoudertB., Bertheault-CvitkovicF., Larregain-FournierD., Le RolA., AdamR., MissetJ.L., LéviF.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. I. Clin. Oncol., 18: 136–147, 2000.
7.
LéviF., ZidaniR., VannetzelJ.M., PerpointB., FocanC., FaggiuoloR., CholletP., GarufiC., ItzhakiM., DogliottiL., IacobelliS., AdamR., KunstlingerF., GastiaburuJ., BismuthH., JasminC., MissetJ.L.,: Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. J. Natl. Cancer Inst., 86: 1608–1617, 1994.
8.
LéviF., ZidaniR., MissetJ.L., VannetzelJ.M., DogliottiL., GarufiC., CholletP., IacobelliS., FocanC., PerpointB.: Le Rol A., Adam R., Kunstlinger F., Itzhaki M.: Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet, 350: 681–686, 1997.
9.
LéviF., ZidaniR., BrienzaS., DogliottiL., PerpointB., RotarskiM., LetourneauY., LloryJ.F., CholletP., Le RolA., FocanC.: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer, 85: 2532–2540, 1999.
10.
GiacchettiS., ItzhakiM., GruiaG., AdamR., ZidaniR., KunstlingerF., BrienzaS., AlafaciE., Bertheault-CvitkovicF., JasminC., ReynesM., BismuthH., MissetJ.L., LéviF.: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol., 10: 663–669, 1999.
